Utility  ||| S:0 E:8 ||| NN
of  ||| S:8 E:11 ||| IN
bioimpedance  ||| S:11 E:24 ||| JJ
spectroscopy  ||| S:24 E:37 ||| NNS
( ||| S:37 E:38 ||| -LRB-
BIS ||| S:38 E:41 ||| NNP
)  ||| S:41 E:43 ||| -RRB-
in  ||| S:43 E:46 ||| IN
the  ||| S:46 E:50 ||| DT
management  ||| S:50 E:61 ||| NN
of  ||| S:61 E:64 ||| IN
refractory  ||| S:64 E:75 ||| JJ
hypertension  ||| S:75 E:88 ||| NN
in  ||| S:88 E:91 ||| IN
patients  ||| S:91 E:100 ||| NNS
with  ||| S:100 E:105 ||| IN
chronic  ||| S:105 E:113 ||| JJ
kidney  ||| S:113 E:120 ||| NN
disease  ||| S:120 E:128 ||| NN
( ||| S:128 E:129 ||| -LRB-
CKD ||| S:129 E:132 ||| NNP
)  ||| S:132 E:134 ||| -RRB-
Expansion  ||| S:134 E:144 ||| NN
of  ||| S:144 E:147 ||| IN
extracellular  ||| S:147 E:161 ||| JJ
volume  ||| S:161 E:168 ||| NN
( ||| S:168 E:169 ||| -LRB-
ECV ||| S:169 E:172 ||| NNP
)  ||| S:172 E:174 ||| -RRB-
is  ||| S:174 E:177 ||| VBZ
a  ||| S:177 E:179 ||| DT
frequent  ||| S:179 E:188 ||| JJ
cause  ||| S:188 E:194 ||| NN
of  ||| S:194 E:197 ||| IN
resistant  ||| S:197 E:207 ||| JJ
hypertension  ||| S:207 E:220 ||| NN
( ||| S:220 E:221 ||| -LRB-
RHT ||| S:221 E:224 ||| NNP
)  ||| S:224 E:226 ||| -RRB-
in  ||| S:226 E:229 ||| IN
patients  ||| S:229 E:238 ||| NNS
with  ||| S:238 E:243 ||| IN
chronic  ||| S:243 E:251 ||| JJ
kidney  ||| S:251 E:258 ||| NN
disease  ||| S:258 E:266 ||| NN
( ||| S:266 E:267 ||| -LRB-
CKD ||| S:267 E:270 ||| NNP
) ||| S:270 E:271 ||| -RRB-
.  ||| S:271 E:273 ||| .
The  ||| S:273 E:277 ||| DT
aim  ||| S:277 E:281 ||| NN
of  ||| S:281 E:284 ||| IN
this  ||| S:284 E:289 ||| DT
exploratory  ||| S:289 E:301 ||| JJ
study  ||| S:301 E:307 ||| NN
was  ||| S:307 E:311 ||| VBD
that  ||| S:311 E:316 ||| IN
of  ||| S:316 E:319 ||| IN
applying  ||| S:319 E:328 ||| VBG
bioimpedance  ||| S:328 E:341 ||| JJ
spectroscopy  ||| S:341 E:354 ||| NNS
( ||| S:354 E:355 ||| -LRB-
BIS ||| S:355 E:358 ||| NNP
)  ||| S:358 E:360 ||| -RRB-
for  ||| S:360 E:364 ||| IN
the  ||| S:364 E:368 ||| DT
identification  ||| S:368 E:383 ||| NN
of  ||| S:383 E:386 ||| IN
CKD  ||| S:386 E:390 ||| NNP
patients  ||| S:390 E:399 ||| NNS
with  ||| S:399 E:404 ||| IN
RHT  ||| S:404 E:408 ||| NNP
and  ||| S:408 E:412 ||| CC
expansion  ||| S:412 E:422 ||| NN
of  ||| S:422 E:425 ||| IN
ECV ||| S:425 E:428 ||| NNP
,  ||| S:428 E:430 ||| ,
while  ||| S:430 E:436 ||| IN
trying  ||| S:436 E:443 ||| VBG
to  ||| S:443 E:446 ||| TO
control  ||| S:446 E:454 ||| VB
blood  ||| S:454 E:460 ||| NN
pressure  ||| S:460 E:469 ||| NN
( ||| S:469 E:470 ||| -LRB-
BP ||| S:470 E:472 ||| NNP
)  ||| S:472 E:474 ||| -RRB-
using  ||| S:474 E:480 ||| VBG
an  ||| S:480 E:483 ||| DT
intensification  ||| S:483 E:499 ||| NN
of  ||| S:499 E:502 ||| IN
diuretic  ||| S:502 E:511 ||| JJ
treatment ||| S:511 E:520 ||| NN
.  ||| S:520 E:522 ||| .
We  ||| S:522 E:525 ||| PRP
included  ||| S:525 E:534 ||| VBD
50  ||| S:534 E:537 ||| CD
patients  ||| S:537 E:546 ||| NNS
with  ||| S:546 E:551 ||| IN
RHT  ||| S:551 E:555 ||| NNP
and  ||| S:555 E:559 ||| CC
CKD  ||| S:559 E:563 ||| NNP
who  ||| S:563 E:567 ||| WP
underwent  ||| S:567 E:577 ||| VBD
BIS ||| S:577 E:580 ||| NNP
.  ||| S:580 E:582 ||| .
In  ||| S:582 E:585 ||| IN
order  ||| S:585 E:591 ||| NN
to  ||| S:591 E:594 ||| TO
control  ||| S:594 E:602 ||| VB
BP ||| S:602 E:604 ||| NNP
,  ||| S:604 E:606 ||| ,
diuretic  ||| S:606 E:615 ||| JJ
treatment  ||| S:615 E:625 ||| NN
was  ||| S:625 E:629 ||| VBD
intensified  ||| S:629 E:641 ||| VBN
in  ||| S:641 E:644 ||| IN
those  ||| S:644 E:650 ||| DT
patients  ||| S:650 E:659 ||| NNS
with  ||| S:659 E:664 ||| IN
expansion  ||| S:664 E:674 ||| NN
of  ||| S:674 E:677 ||| IN
the  ||| S:677 E:681 ||| DT
ECV ||| S:681 E:684 ||| NNP
.  ||| S:684 E:686 ||| .
In  ||| S:686 E:689 ||| IN
all  ||| S:689 E:693 ||| DT
other  ||| S:693 E:699 ||| JJ
cases ||| S:699 E:704 ||| NNS
,  ||| S:704 E:706 ||| ,
another  ||| S:706 E:714 ||| DT
antihypertensive  ||| S:714 E:731 ||| JJ
drug  ||| S:731 E:736 ||| NN
was  ||| S:736 E:740 ||| VBD
added ||| S:740 E:745 ||| VBN
.  ||| S:745 E:747 ||| .
The  ||| S:747 E:751 ||| DT
mean  ||| S:751 E:756 ||| JJ
age  ||| S:756 E:760 ||| NN
was  ||| S:760 E:764 ||| VBD
68.2  ||| S:764 E:769 ||| CD
±  ||| S:769 E:771 ||| CD
10.4  ||| S:771 E:776 ||| CD
years ||| S:776 E:781 ||| NNS
,  ||| S:781 E:783 ||| ,
68 ||| S:783 E:785 ||| CD
%  ||| S:785 E:787 ||| NN
were  ||| S:787 E:792 ||| VBD
male  ||| S:792 E:797 ||| JJ
and  ||| S:797 E:801 ||| CC
58 ||| S:801 E:803 ||| CD
%  ||| S:803 E:805 ||| NN
were  ||| S:805 E:810 ||| VBD
diabetic ||| S:810 E:818 ||| VBN
.  ||| S:818 E:820 ||| .
The  ||| S:820 E:824 ||| DT
mean  ||| S:824 E:829 ||| VBP
estimated  ||| S:829 E:839 ||| VBN
glomerular  ||| S:839 E:850 ||| JJ
filtration  ||| S:850 E:861 ||| JJ
rate  ||| S:861 E:866 ||| NN
( ||| S:866 E:867 ||| -LRB-
eGFR ||| S:867 E:871 ||| NNP
)  ||| S:871 E:873 ||| -RRB-
was  ||| S:873 E:877 ||| VBD
50.7  ||| S:877 E:882 ||| CD
±  ||| S:882 E:884 ||| CD
22.4  ||| S:884 E:889 ||| CD
mL ||| S:889 E:891 ||| JJ
/ ||| S:891 E:892 ||| FW
min ||| S:892 E:895 ||| FW
/ ||| S:895 E:896 ||| FW
1.72  ||| S:896 E:901 ||| FW
m ||| S:901 E:902 ||| FW
( ||| S:902 E:903 ||| -LRB-
2 ||| S:903 E:904 ||| LS
) ||| S:904 E:905 ||| -RRB-
.  ||| S:905 E:907 ||| .
Baseline  ||| S:907 E:916 ||| NNP
systolic  ||| S:916 E:925 ||| VBD
BP  ||| S:925 E:928 ||| NNP
was  ||| S:928 E:932 ||| VBD
167.2  ||| S:932 E:938 ||| CD
±  ||| S:938 E:940 ||| CD
8.6  ||| S:940 E:944 ||| CD
mmHg  ||| S:944 E:949 ||| JJ
and  ||| S:949 E:953 ||| CC
diastolic  ||| S:953 E:963 ||| JJ
BP  ||| S:963 E:966 ||| NNP
was  ||| S:966 E:970 ||| VBD
84.8  ||| S:970 E:975 ||| CD
±  ||| S:975 E:977 ||| CD
9.5  ||| S:977 E:981 ||| CD
mmHg ||| S:981 E:985 ||| NN
.  ||| S:985 E:987 ||| .
The  ||| S:987 E:991 ||| DT
mean  ||| S:991 E:996 ||| JJ
number  ||| S:996 E:1003 ||| NN
of  ||| S:1003 E:1006 ||| IN
antihypertensive  ||| S:1006 E:1023 ||| JJ
drugs  ||| S:1023 E:1029 ||| NNS
received  ||| S:1029 E:1038 ||| VBD
was  ||| S:1038 E:1042 ||| VBD
3.8  ||| S:1042 E:1046 ||| CD
±  ||| S:1046 E:1048 ||| CD
0.9 ||| S:1048 E:1051 ||| CD
.  ||| S:1051 E:1053 ||| .
Expansion  ||| S:1053 E:1063 ||| NN
of  ||| S:1063 E:1066 ||| IN
ECV  ||| S:1066 E:1070 ||| NNP
was  ||| S:1070 E:1074 ||| VBD
recorded  ||| S:1074 E:1083 ||| VBN
in  ||| S:1083 E:1086 ||| IN
30  ||| S:1086 E:1089 ||| CD
( ||| S:1089 E:1090 ||| -LRB-
60 ||| S:1090 E:1092 ||| CD
% ||| S:1092 E:1093 ||| NN
)  ||| S:1093 E:1095 ||| -RRB-
patients  ||| S:1095 E:1104 ||| NNS
and  ||| S:1104 E:1108 ||| CC
was  ||| S:1108 E:1112 ||| VBD
more  ||| S:1112 E:1117 ||| RBR
frequent  ||| S:1117 E:1126 ||| JJ
in  ||| S:1126 E:1129 ||| IN
diabetics  ||| S:1129 E:1139 ||| NNS
and  ||| S:1139 E:1143 ||| CC
in  ||| S:1143 E:1146 ||| IN
patients  ||| S:1146 E:1155 ||| NNS
with  ||| S:1155 E:1160 ||| IN
more  ||| S:1160 E:1165 ||| JJR
albuminuria ||| S:1165 E:1176 ||| NN
.  ||| S:1176 E:1178 ||| .
At  ||| S:1178 E:1181 ||| IN
6  ||| S:1181 E:1183 ||| CD
months  ||| S:1183 E:1190 ||| NNS
of  ||| S:1190 E:1193 ||| IN
follow-up ||| S:1193 E:1202 ||| NNP
,  ||| S:1202 E:1204 ||| ,
a  ||| S:1204 E:1206 ||| DT
decline  ||| S:1206 E:1214 ||| NN
of  ||| S:1214 E:1217 ||| IN
21.4  ||| S:1217 E:1222 ||| CD
±  ||| S:1222 E:1224 ||| CD
7.1  ||| S:1224 E:1228 ||| CD
mmHg  ||| S:1228 E:1233 ||| NN
was  ||| S:1233 E:1237 ||| VBD
observed  ||| S:1237 E:1246 ||| VBN
in  ||| S:1246 E:1249 ||| IN
systolic  ||| S:1249 E:1258 ||| JJ
BP  ||| S:1258 E:1261 ||| NNP
in  ||| S:1261 E:1264 ||| IN
the  ||| S:1264 E:1268 ||| DT
patients  ||| S:1268 E:1277 ||| NNS
with  ||| S:1277 E:1282 ||| IN
expansion  ||| S:1282 E:1292 ||| NN
of  ||| S:1292 E:1295 ||| IN
ECV ||| S:1295 E:1298 ||| NNP
,  ||| S:1298 E:1300 ||| ,
compared  ||| S:1300 E:1309 ||| VBN
with  ||| S:1309 E:1314 ||| IN
a  ||| S:1314 E:1316 ||| DT
decrease  ||| S:1316 E:1325 ||| NN
of  ||| S:1325 E:1328 ||| IN
9.4  ||| S:1328 E:1332 ||| CD
±  ||| S:1332 E:1334 ||| CD
3.4  ||| S:1334 E:1338 ||| CD
mmHg  ||| S:1338 E:1343 ||| NN
in  ||| S:1343 E:1346 ||| IN
the  ||| S:1346 E:1350 ||| DT
normal  ||| S:1350 E:1357 ||| JJ
ECV  ||| S:1357 E:1361 ||| NNP
group  ||| S:1361 E:1367 ||| NN
( ||| S:1367 E:1368 ||| -LRB-
P  ||| S:1368 E:1370 ||| NNP
< ||| S:1370 E:1372 ||| SYM
0.01 ||| S:1372 E:1376 ||| CD
) ||| S:1376 E:1377 ||| -RRB-
.  ||| S:1377 E:1379 ||| .
We  ||| S:1379 E:1382 ||| PRP
did  ||| S:1382 E:1386 ||| VBD
not  ||| S:1386 E:1390 ||| RB
find  ||| S:1390 E:1395 ||| VB
differences  ||| S:1395 E:1407 ||| NNS
in  ||| S:1407 E:1410 ||| IN
the  ||| S:1410 E:1414 ||| DT
decrease  ||| S:1414 E:1423 ||| NN
in  ||| S:1423 E:1426 ||| IN
diastolic  ||| S:1426 E:1436 ||| JJ
BP  ||| S:1436 E:1439 ||| NNP
between  ||| S:1439 E:1447 ||| IN
the  ||| S:1447 E:1451 ||| DT
groups ||| S:1451 E:1457 ||| NNS
.  ||| S:1457 E:1459 ||| .
Nine  ||| S:1459 E:1464 ||| CD
patients  ||| S:1464 E:1473 ||| NNS
( ||| S:1473 E:1474 ||| -LRB-
30 ||| S:1474 E:1476 ||| CD
% ||| S:1476 E:1477 ||| NN
)  ||| S:1477 E:1479 ||| -RRB-
with  ||| S:1479 E:1484 ||| IN
ECV  ||| S:1484 E:1488 ||| NNP
expansion  ||| S:1488 E:1498 ||| NN
who  ||| S:1498 E:1502 ||| WP
increased  ||| S:1502 E:1512 ||| VBD
diuretic  ||| S:1512 E:1521 ||| JJ
therapy  ||| S:1521 E:1529 ||| NN
reached  ||| S:1529 E:1537 ||| VBD
the  ||| S:1537 E:1541 ||| DT
target  ||| S:1541 E:1548 ||| NN
blood  ||| S:1548 E:1554 ||| NN
pressure  ||| S:1554 E:1563 ||| NN
( ||| S:1563 E:1564 ||| -LRB-
BP ||| S:1564 E:1566 ||| NNP
)  ||| S:1566 E:1568 ||| -RRB-
of  ||| S:1568 E:1571 ||| IN
< ||| S:1571 E:1572 ||| SYM
140 ||| S:1572 E:1575 ||| CD
/ ||| S:1575 E:1576 ||| CD
90  ||| S:1576 E:1579 ||| CD
mmHg ||| S:1579 E:1583 ||| NN
,  ||| S:1583 E:1585 ||| ,
when  ||| S:1585 E:1590 ||| WRB
compared  ||| S:1590 E:1599 ||| VBN
with  ||| S:1599 E:1604 ||| IN
only  ||| S:1604 E:1609 ||| RB
two  ||| S:1609 E:1613 ||| CD
patients  ||| S:1613 E:1622 ||| NNS
( ||| S:1622 E:1623 ||| -LRB-
10 ||| S:1623 E:1625 ||| CD
% ||| S:1625 E:1626 ||| NN
)  ||| S:1626 E:1628 ||| -RRB-
who  ||| S:1628 E:1632 ||| WP
had  ||| S:1632 E:1636 ||| VBD
normal  ||| S:1636 E:1643 ||| JJ
ECV  ||| S:1643 E:1647 ||| NNP
and  ||| S:1647 E:1651 ||| CC
in  ||| S:1651 E:1654 ||| IN
whom  ||| S:1654 E:1659 ||| WP
other  ||| S:1659 E:1665 ||| JJ
antihypertensive  ||| S:1665 E:1682 ||| JJ
drug  ||| S:1682 E:1687 ||| NN
was  ||| S:1687 E:1691 ||| VBD
added ||| S:1691 E:1696 ||| VBN
.  ||| S:1696 E:1698 ||| .
A  ||| S:1698 E:1700 ||| DT
total  ||| S:1700 E:1706 ||| JJ
decrease  ||| S:1706 E:1715 ||| NN
in  ||| S:1715 E:1718 ||| IN
body  ||| S:1718 E:1723 ||| NN
water  ||| S:1723 E:1729 ||| NN
of  ||| S:1729 E:1732 ||| IN
1.9  ||| S:1732 E:1736 ||| CD
±  ||| S:1736 E:1738 ||| CD
1.1  ||| S:1738 E:1742 ||| CD
L  ||| S:1742 E:1744 ||| NNP
was  ||| S:1744 E:1748 ||| VBD
observed  ||| S:1748 E:1757 ||| VBN
in  ||| S:1757 E:1760 ||| IN
patients  ||| S:1760 E:1769 ||| NNS
with  ||| S:1769 E:1774 ||| IN
ECV  ||| S:1774 E:1778 ||| NNP
expansion  ||| S:1778 E:1788 ||| NN
who  ||| S:1788 E:1792 ||| WP
intensified  ||| S:1792 E:1804 ||| VBD
diuretic  ||| S:1804 E:1813 ||| JJ
treatment  ||| S:1813 E:1823 ||| NN
at  ||| S:1823 E:1826 ||| IN
the  ||| S:1826 E:1830 ||| DT
expense  ||| S:1830 E:1838 ||| NN
of  ||| S:1838 E:1841 ||| IN
a  ||| S:1841 E:1843 ||| DT
decline  ||| S:1843 E:1851 ||| NN
in  ||| S:1851 E:1854 ||| IN
ECV  ||| S:1854 E:1858 ||| NNP
of  ||| S:1858 E:1861 ||| IN
1.1  ||| S:1861 E:1865 ||| CD
±  ||| S:1865 E:1867 ||| CD
1  ||| S:1867 E:1869 ||| CD
L.  ||| S:1869 E:1872 ||| NNP
eGFR  ||| S:1872 E:1877 ||| NNP
remained  ||| S:1877 E:1886 ||| VBD
stable  ||| S:1886 E:1893 ||| JJ
in  ||| S:1893 E:1896 ||| IN
both  ||| S:1896 E:1901 ||| DT
groups  ||| S:1901 E:1908 ||| NNS
( ||| S:1908 E:1909 ||| -LRB-
47.1  ||| S:1909 E:1914 ||| FW
±  ||| S:1914 E:1916 ||| FW
21.1  ||| S:1916 E:1921 ||| FW
versus  ||| S:1921 E:1928 ||| FW
54.1  ||| S:1928 E:1933 ||| FW
±  ||| S:1933 E:1935 ||| FW
25.2  ||| S:1935 E:1940 ||| FW
mL ||| S:1940 E:1942 ||| FW
/ ||| S:1942 E:1943 ||| FW
min ||| S:1943 E:1946 ||| FW
/ ||| S:1946 E:1947 ||| FW
1.73  ||| S:1947 E:1952 ||| FW
m ||| S:1952 E:1953 ||| FW
( ||| S:1953 E:1954 ||| -LRB-
2 ||| S:1954 E:1955 ||| LS
) ||| S:1955 E:1956 ||| -RRB-
;  ||| S:1956 E:1958 ||| :
P  ||| S:1958 E:1960 ||| NN
=  ||| S:1960 E:1962 ||| SYM
0.37 ||| S:1962 E:1966 ||| CD
) ||| S:1966 E:1967 ||| -RRB-
.  ||| S:1967 E:1969 ||| .
An  ||| S:1969 E:1972 ||| DT
increase  ||| S:1972 E:1981 ||| NN
in  ||| S:1981 E:1984 ||| IN
ECV  ||| S:1984 E:1988 ||| NNP
as  ||| S:1988 E:1991 ||| RB
measured  ||| S:1991 E:2000 ||| VBN
by  ||| S:2000 E:2003 ||| IN
BIS  ||| S:2003 E:2007 ||| NNP
frequently  ||| S:2007 E:2018 ||| RB
occurs  ||| S:2018 E:2025 ||| VBZ
in  ||| S:2025 E:2028 ||| IN
RHT  ||| S:2028 E:2032 ||| NNP
in  ||| S:2032 E:2035 ||| IN
patients  ||| S:2035 E:2044 ||| NNS
with  ||| S:2044 E:2049 ||| IN
CKD ||| S:2049 E:2052 ||| NNP
.  ||| S:2052 E:2054 ||| .
Diabetic  ||| S:2054 E:2063 ||| NNP
and  ||| S:2063 E:2067 ||| CC
severe  ||| S:2067 E:2074 ||| JJ
proteinuric  ||| S:2074 E:2086 ||| JJ
patients  ||| S:2086 E:2095 ||| NNS
are  ||| S:2095 E:2099 ||| VBP
more  ||| S:2099 E:2104 ||| RBR
exposed  ||| S:2104 E:2112 ||| VBN
to  ||| S:2112 E:2115 ||| TO
expansion  ||| S:2115 E:2125 ||| NN
of  ||| S:2125 E:2128 ||| IN
ECV ||| S:2128 E:2131 ||| NNP
.  ||| S:2131 E:2133 ||| .
BIS  ||| S:2133 E:2137 ||| NNP
is  ||| S:2137 E:2140 ||| VBZ
a  ||| S:2140 E:2142 ||| DT
potentially  ||| S:2142 E:2154 ||| RB
useful  ||| S:2154 E:2161 ||| JJ
method  ||| S:2161 E:2168 ||| NN
for  ||| S:2168 E:2172 ||| IN
identifying  ||| S:2172 E:2184 ||| VBG
and  ||| S:2184 E:2188 ||| CC
treating  ||| S:2188 E:2197 ||| VBG
patients  ||| S:2197 E:2206 ||| NNS
with  ||| S:2206 E:2211 ||| IN
RHT  ||| S:2211 E:2215 ||| NNP
and  ||| S:2215 E:2219 ||| CC
expansion  ||| S:2219 E:2229 ||| NN
of  ||| S:2229 E:2232 ||| IN
ECV ||| S:2232 E:2235 ||| NNP
.  ||| S:2235 E:2237 ||| .
The  ||| S:2237 E:2241 ||| DT
hypothesis  ||| S:2241 E:2252 ||| NN
generated  ||| S:2252 E:2262 ||| VBD
by  ||| S:2262 E:2265 ||| IN
this  ||| S:2265 E:2270 ||| DT
exploratory  ||| S:2270 E:2282 ||| JJ
study  ||| S:2282 E:2288 ||| NN
needs  ||| S:2288 E:2294 ||| VBZ
to  ||| S:2294 E:2297 ||| TO
be  ||| S:2297 E:2300 ||| VB
tested  ||| S:2300 E:2307 ||| VBN
in  ||| S:2307 E:2310 ||| IN
a  ||| S:2310 E:2312 ||| DT
randomized  ||| S:2312 E:2323 ||| JJ
clinical  ||| S:2323 E:2332 ||| JJ
trial ||| S:2332 E:2337 ||| NN
.  ||| S:2337 E:2339 ||| .
